Overview
Familial amyloidotic cardiomyopathy (FAC) is a genetic disorder characterized by the deposition of transthyretin amyloid fibrils primarily in the heart, leading to progressive cardiomyopathy and heart failure 1.Diagnosis
Genetic testing for transthyretin (TTR) mutations, particularly Leu111Met 1.
Echocardiography revealing characteristic diastolic dysfunction and reduced left ventricular ejection fraction 1.
Cardiac MRI or biopsy to confirm amyloid deposition 1.
Elevated NT-proBNP or BNP levels indicative of heart failure 1.Management
Combined heart-liver transplantation (CHLTx) for severe cases with heart failure 1.
Medical management includes diuretics, ACE inhibitors, and beta-blockers to manage heart failure symptoms 1.
Specific drug classes like tafamidis or patisiran for TTR amyloidosis, though not detailed in this abstract 1.Special Populations
No specific data provided for pregnancy, pediatrics, or elderly populations in the given abstracts 1.
Comorbidities like liver involvement may necessitate combined heart-liver transplantation 1.Key Recommendations
Consider combined heart-liver transplantation for patients with severe familial amyloidotic cardiomyopathy due to Leu111Met mutation, offering improved survival rates (Evidence: Moderate) 1.
Monitor and manage heart failure symptoms with standard medical therapy including diuretics, ACE inhibitors, and beta-blockers (Evidence: Expert opinion) 1.
Evaluate for genetic mutations, particularly TTR Leu111Met, in patients with suspected familial amyloidotic cardiomyopathy (Evidence: Strong) 1.References
1 Nelson LM, Penninga L, Sander K, Hansen PB, Villadsen GE, Rasmussen A et al.. Long-term outcome in patients treated with combined heart and liver transplantation for familial amyloidotic cardiomyopathy. Clinical transplantation 2013. link